Last reviewed · How we verify
VAX2012Q
At a glance
| Generic name | VAX2012Q |
|---|---|
| Also known as | Quadrivalent Recombinant Hemagglutinin Influenza Vaccine, RIV4, Quadrivalent Recombinant Hemagglutinin Influenza vaccine |
| Sponsor | VaxInnate Corporation |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years (PHASE2)
- Study of Safety and Immunogenicity of a Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years (PHASE1, PHASE2)
- Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VAX2012Q CI brief — competitive landscape report
- VAX2012Q updates RSS · CI watch RSS
- VaxInnate Corporation portfolio CI